IP Library Granted Patent US 8,263,667
Granted Patent B2
US 8,263,667 · App. 13/043,133 · Granted Sep 11, 2012

Nutritional supplement for use under physiologically stressful conditions

Assignee: Vertical Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,667
App. No.
13/043,133
Granted
Sep 11, 2012
Kind
B2
Abstract

A nutritional supplement for use in physiologically stressful conditions is disclosed. The nutritional supplement may include one or more of vitamin A, vitamin E, vitamin D3, vitamin C, vitamin B1, riboflavin, niacin, folic acid, vitamin B 6 , biotin, pantothenic acid, vitamin B 12 , magnesium, zinc, selenium, chromium, copper, iron, alpha lipoic acid, lutein and lycopene.

Claims (22)

1. A composition, consisting essentially of:

about 750 IUs to about 1500 IUs of vitamin A, about 125 IUs to about 250 IUs of vitamin E, about 600 IUs to about 1800 IUs of vitamin D3, about 375 mg to about 750 mg of vitamin C, about 25 mg to about 50 mg of vitamin B1, about 3.4 mg to about 6.8 mg of riboflavin, about 35 mg to about 70 mg of niacin, about 1.25 mg to about 2.5 mg of folic acid, about 35 mg to about 70 mg of vitamin B6, about 75 mcg of biotin, about 5 mg to about 10 mg pantothenic acid, about 70 mcg to about 140 mcg of vitamin B12, about 35 mg to about 70 mg of magnesium, about 35 mg to about 70 mg of zinc, about 125 mcg to about 250 mcg of selenium, about 150 mcg to about 300 mcg of chromium, about 1 mg to about 2 mg of copper, about a trace amount to about 1 mg of added iron, about 10 mg to about 20 mg of alpha lipoic acid, about 350 mcg to about 700 mcg of lutein, and about 125 mcg to about 250 mcg of lycopene.

2. A composition, consisting essentially of:

about 750 IUs of vitamin A, about 125 IUs of vitamin E, about 1200 IUs of vitamin D3, about 375 mg of vitamin C, about 25 mg of vitamin B1, about 3.4 mg of riboflavin, about 35 mg of niacin, about 1.25 mg of folic acid, about 35 mg of vitamin B6, about 75 mcg of biotin, about 5 mg of pantothenic acid, about 70 mcg of vitamin B12, about 35 mg of magnesium, about 35 mg of zinc, about 125 mcg of selenium, about 150 mcg of chromium, about 1 mg of copper, about a trace amount of added iron, about 10 mg of alpha lipoic acid, about 350 mcg of lutein and about 125 mcg of lycopene.

3. A dosing formulation of a composition, the dosing formulation comprising a single dose formulation of the composition, wherein the composition consists essentially of:

about 750 IUs to about 1500 IUs of vitamin A, about 125 IUs to about 250 IUs of vitamin E, about 600 IUs to about 1800 IUs of vitamin D3, about 375 mg to about 750 mg of vitamin C, about 25 mg to about 50 mg of vitamin B1, about 3.4 mg to about 6.8 mg of riboflavin, about 35 mg to about 70 mg of niacin, about 1.25 mg to about 2.5 mg of folic acid, about 35 mg to about 70 mg of vitamin B6, about 75 mcg of biotin, about 5 mg to about 10 mg pantothenic acid, about 70 mcg to about 140 mcg of vitamin B12, about 35 mg to about 70 mg of magnesium, about 35 mg to about 70 mg of zinc, about 125 mcg to about 250 mcg of selenium, about 150 mcg to about 300 mcg of chromium, about 1 mg to about 2 mg of copper, about a trace amount to about 1 mg of added iron, about 10 mg to about 20 mg of alpha lipoic acid, about 350 mcg to about 700 mcg of lutein, and about 125 mcg to about 250 mcg of lycopene.

4. The dosing formulation of claim 3 , wherein the single dosage formulation is selected from the group consisting of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, an effervescent tablet, a hard gelatin capsule, and a soft gelatin capsule.

5. The dosing formulation of claim 3 , wherein the single dosage formulation consists essentially of an enteric coating.

6. The dosing formulation of claim 3 , wherein the single dosage formulation consists essentially of a liquid suspension.

7. The dosing formulation of claim 3 , wherein the single dosage formulation consists essentially of a food product.

8. A dosing formulation of a composition, the dosing formulation comprising a single dose formulation of the composition, wherein the composition consists essentially of:

about 750 IUs of vitamin A, about 125 IUs of vitamin E, about 1200 IUs of vitamin D3, about 375 mg of vitamin C, about 25 mg of vitamin B1, about 3.4 mg of riboflavin, about 35 mg of niacin, about 1.25 mg of folic acid, about 35 mg of vitamin B6, about 75 mcg of biotin, about 5 mg of pantothenic acid, about 70 mcg of vitamin B12, about 35 mg of magnesium, about 35 mg of zinc, about 125 mcg of selenium, about 150 mcg of chromium, about 1 mg of copper, about a trace amount of added iron, about 10 mg of alpha lipoic acid, about 350 mcg of lutein and about 125 mcg of lycopene in a pharmaceutically acceptable single dosage formulation.

9. The dosing formulation of claim 8 , wherein the single dosage formulation is selected from the group consisting of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, an effervescent tablet, a hard gelatin capsule, and a soft gelatin capsule.

10. The dosing formulation of claim 8 , wherein the single dosage formulation consists essentially of an enteric coating.

11. The dosing formulation of claim 8 , wherein the single dosage formulation consists essentially of a liquid suspension.

12. The dosing formulation of claim 8 , wherein the single dosage formulation consists essentially of a food product.

13. A method of treating physiological conditions in response to stressful situations comprising:

administering to an individual a composition consisting essentially of:

about 750 IUs to about 1500 IUs of vitamin A, about 125 IUs to about 250 IUs of vitamin E, about 600 IUs to about 1800 IUs of vitamin D3, about 375 mg to about 750 mg of vitamin C, about 25 mg to about 50 mg of vitamin B1, about 3.4 mg to about 6.8 mg of riboflavin, about 35 mg to about 70 mg of niacin, about 1.25 mg to about 2.5 mg of folic acid, about 35 mg to about 70 mg of vitamin B6, about 75 mcg of biotin, about 5 mg to about 10 mg pantothenic acid, about 70 mcg to about 140 mcg of vitamin B12, about 35 mg to about 70 mg of magnesium, about 35 mg to about 70 mg of zinc, about 125 mcg to about 250 mcg of selenium, about 150 mcg to about 300 mcg of chromium, about 1 mg to about 2 mg of copper, about a trace amount to about 1 mg of added iron, about 10 mg to about 20 mg of alpha lipoic acid, about 350 mcg to about 700 mcg of lutein, and about 125 mcg to about 250 mcg of lycopene.

14. A method of treating physiological conditions in response to stressful situations comprising:

administering to an individual a composition consisting essentially of:

about 750 IUs of vitamin A, about 125 IUs of vitamin E, about 1200 IUs of vitamin D3, about 375 mg of vitamin C, about 25 mg of vitamin B1, about 3.4 mg of riboflavin, about 35 mg of niacin, about 1.25 mg of folic acid, about 35 mg of vitamin B6, about 75 mcg of biotin, about 5 mg of pantothenic acid, about 70 mcg of vitamin B12, about 35 mg of magnesium, about 35 mg of zinc, about 125 mcg of selenium, about 150 mcg of chromium, about 1 mg of copper, about a trace amount of added iron, about 10 mg of alpha lipoic acid, about 350 mcg of lutein and about 125 mcg of lycopene.

Assignments (6)
SECURITY INTEREST Recorded Jun 30, 2023
From: VERTICAL PHARMACEUTICALS, LLC
To: CIBC BANK USA
Reel/Frame 064133/0094 →
RELEASE OF SECURITY INTEREST Recorded Aug 28, 2021
From: CIT BANK, N.A., AS COLLATERAL AGENT
To: VERTICAL PHARMACEUTICALS, LLC
Reel/Frame 057319/0886 →
SECURITY INTEREST Recorded Aug 27, 2021
From: VERTICAL PHARMACEUTICALS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 057309/0950 →
SECURITY INTEREST Recorded Feb 3, 2016
From: VERTICAL PHARMACEUTICALS, LLC
To: CIT BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 037656/0879 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2013
From: VERTICAL PHARMACEUTICALS, INC.
To: SDK VC PHARMA HOLDING CORP.
Reel/Frame 031767/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2013
From: SDK VC PHARMA HOLDING CORP.
To: VERTICAL PHARMACEUTICALS, LLC
Reel/Frame 031767/0691 →
Continuity (3)
Continuation 12698174 · Feb 2, 2010
Continuation In Part 11197757 · Aug 4, 2005
Related Publication 20110159055A1 · Jun 30, 2011